IL2 and COVID-19: Specifically, interleukin-1β (IL-1β), IL-2, IL-6, IL-7, IL-17, tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), C-X-C motif chemokine ligand 10 (CXCL10), and C-C motif chemokine ligand 3 (CCL3) were reported to be upregulated in patients with severe COVID-19, especially among patients treated in intensive care units (ICUs) [12,13].